14 April 2022 - Regeneron continues to progress its next generation antibodies, and has initiated a first in human trial. ...
30 March 2022 - The FDA approval of the first dispersible single tablet regimen containing dolutegravir increases age-appropriate treatment options ...
24 March 2022 - Recommendation based on Phase 3 PROVENT trial showing a significant reduction in the risk of developing ...
18 March 2022 - Opdualag is a first in class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and ...
17 March 2022 - ZYNRELEF is the first and only extended-release local anaesthetic approved by Health Canada. ...
15 March 2022 - Agency supports development of complex generic drug-device combination product to improve competition and access to more affordable ...
25 February 2022 - Amylyx Pharmaceuticals today announced that its marketing authorisation application to the EMA CHMP for AMX0035 (sodium phenylbutyrate ...
27 January 2022 - The EMA’s CHMP has recommended granting a conditional marketing authorisation for the oral antiviral medicine Paxlovid ...
14 January 2022 - Ryaltris will be marketed and distributed in the United States through its partner Hikma. ...
11 January 2022 - More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic ...
10 January 2022 - EMA has started evaluating an application for a conditional marketing authorisation for the oral antiviral medicine ...
4 January 2022 - Amylyx Pharmaceuticals today announced it has submitted a marketing authorisation application to the EMA's CHMP for ...
4 January 2022 - On 4 January 2022, the TGA granted a further provisional determination to AstraZeneca in relation to ...
29 December 2021 - Amylyx Pharmaceuticals today announced that the U.S. FDA has accepted for review its new drug application for ...
13 December 2021 - Commercialisation will start early calendar year 2022. ...